Building Long-term Shareholder Value
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is a biopharmaceutical company
focused on the research, development and commercialization of products that
address unmet medical needs in the acute care environment. Our historically
successful IV antibiotic CUBICIN® (daptomycin for injection) serves
as the strategic and operational foundation for building shareholder value.
Cubist anticipates that CUBICIN will achieve peak sales of > $1 billion annually
in the U.S.
What's next for Cubist?
Cubist is moving forward confidently and successfully as an acute care-focused therapeutics company. Our most recent financial results were announced on April 18, 2012.
Click Here
to receive more information from Cubist Pharmaceuticals | 
